Sanofi Says It Won EU Patent Ruling Against Amgen Over Cholesterol Drug
29 Octobre 2020 - 3:58PM
Dow Jones News
By Kim Richters
Sanofi SA said Thursday that the European Patent Office had
ruled in favor of Sanofi and Regeneron Pharmaceuticals Inc. in a
patent case related to their cholesterol drug Praluent.
The French pharmaceutical company said the European authority's
ruling invalidated certain European patent claims made by Amgen
Inc. concerning PCSK9 antibodies relevant to the drug.
U.S. pharmaceutical company Amgen wasn't immediately available
for comment.
Sanofi said it owns the rights for the drug outside of the U.S.,
while Regeneron holds them inside the country.
Praluent continues to be on the market in the European countries
where it is approved, with the exception of Germany following an
injunction in July last year, which Sanofi said it has
appealed.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
October 29, 2020 10:43 ET (14:43 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
